The acquisition brings FB102, a first-in-class anti-CD122 antibody, into the immunology pipeline, supporting growth ambitions and expanding the portfolio into large autoimmune indications like vitiligo and celiac disease. The $2.2B cash deal leverages proven development and commercialization strate…
argenx will acquire Forte Biosciences for $2.2 billion, adding the first-in-class anti-CD122 antibody FB102 to its immunology pipeline. The deal, expected to close in Q3 2026, aims to accelerate development for multiple autoimmune diseases and strengthen long-term growth.Original document: argenx S…
argenx (EURONEXT:ARGX) posted strong Q2 2026 results—$1.5B sales up 60% YoY, operating profit +146%—driven by VYVGART growth as R&D/SG&A rise; multiple registrational readouts due H2 2026–H2 2027 while analysts lift price targets and maintain buy ratings.Previous Week Recap This is an A…
July 27, 2026 – 7:00 AM CETAmsterdam, the Netherlands and Dallas, Texas – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company, and Forte Biosciences, Inc. NASDAQ:FBRX today announced that the companies have entered into a definitive agreement under which argenx will acquire Fo…
Q2 2026 saw 60% year-over-year net sales growth to $1.5B and a 146% increase in operating profit, driven by VYVGART's expanded label and strong commercial momentum in MG and CIDP. Cash and financial assets totaled $5.2B at quarter end.Original document: argenx SE [ARGX] Slides Release — Jul. 23 202…
ARGX Q2 2026: sales up 60% year‑over‑year. Company credits expanded Vyvgart indications and pipeline progress. Global Vyvgart product sales higher versus Q2 2025.argenx expanded U.
